{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:26:06Z","timestamp":1781645166852,"version":"3.54.5"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014461","name":"National Institute for Health Research Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ejca.2020.04.032","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T18:55:05Z","timestamp":1592420105000},"page":"103-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position"],"prefix":"10.1016","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4798-8899","authenticated-orcid":false,"given":"Antonin","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna D.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Chargari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Moehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Verheij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Durand-Labrunie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Kissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"Chirat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Burtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Boige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.04.032_bib1","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0016-5107(84)72448-5","article-title":"Endoscopic therapy for esophageal carcinoma with Nd:YAG laser: prospective evaluation of efficacy, complications, and survival","volume":"30","author":"Mellow","year":"1984","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.ejca.2020.04.032_bib2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2019.37.4_suppl.133","article-title":"Prognostic value of nutritional status for esophageal cancer patients undergoing neoadjuvant therapy and resection","volume":"37","author":"Saeed","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib3","first-page":"3587","article-title":"Long-term follow-up of the potential benefits of early nutritional intervention in adults with upper gastrointestinal cancer: a pilot randomised trial","volume":"25","author":"Furness","year":"2017","journal-title":"Support Care Canc"},{"key":"10.1016\/j.ejca.2020.04.032_bib4","doi-asserted-by":"crossref","first-page":"v50","DOI":"10.1093\/annonc\/mdw329","article-title":"Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Lordick","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib5","unstructured":"https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/esophageal_blocks.pdf; accessed 20 April 2020."},{"key":"10.1016\/j.ejca.2020.04.032_bib6","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/annonc\/mdf273","article-title":"A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer","volume":"13","author":"Tebbutt","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1470-2045(14)70028-2","article-title":"Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5\/ACCORD17): final results of a randomised, phase 2\/3 trial","volume":"15","author":"Conroy","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib8","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJM199206113262403","article-title":"Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus","volume":"326","author":"Herskovic","year":"1992","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2020.04.032_bib9","article-title":"Chemotherapy for advanced gastric cancer","volume":"29","author":"Wagner","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejca.2020.04.032_bib10","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1200\/JCO.2002.08.105","article-title":"Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer","volume":"20","author":"Ross","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib11","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ejca.2012.09.025","article-title":"The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)","volume":"49","author":"Al-Batran","year":"2013","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.04.032_bib12","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.2006.08.0135","article-title":"Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research","volume":"25","author":"Roth","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s12032-016-0774-4","article-title":"A pilot trial of FLOT neoadjuvant chemotherapy for resectable esophagogastric junction adenocarcinoma","volume":"33","author":"Al-Fakeeh","year":"2016","journal-title":"Med Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib14","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1200\/JCO.2006.08.3956","article-title":"Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group","volume":"25","author":"Ajani","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2020.04.032_bib16","first-page":"316","article-title":"A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus","volume":"6","author":"Ilson","year":"2000","journal-title":"Canc J"},{"key":"10.1016\/j.ejca.2020.04.032_bib17","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.1999.17.10.3270","article-title":"Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer","volume":"17","author":"Ilson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.dld.2013.10.012","article-title":"Chemotherapy versus self-expanding metal stent as primary treatment of severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer","volume":"46","author":"Touchefeu","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ejca.2020.04.032_bib19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","article-title":"COUGAR-02 Investigators. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial","volume":"15","author":"Ford","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib20","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1200\/JCO.2011.39.4585","article-title":"Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone","volume":"30","author":"Kang","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/annonc\/mdv625","article-title":"Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma","volume":"27","author":"Al-Batran","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib22","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1200\/JCO.2019.37.15_suppl.4010","article-title":"Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase 3 KEYNOTE-181 study","volume":"37","author":"Shah","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib23","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in advanced esophageal squamous cell carcinoma (ESCC): the phase 3 ATTRACTION-3 study","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib24","first-page":"CD005048","article-title":"Interventions for dysphagia in oesophageal cancer","volume":"30","author":"Dai","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejca.2020.04.032_bib25","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1055\/s-0042-114210","article-title":"Esophageal stenting for benign and malignant disease: European society of gastrointestinal endoscopy (ESGE) clinical guideline","volume":"48","author":"Spaander","year":"2016","journal-title":"Endoscopy"},{"key":"10.1016\/j.ejca.2020.04.032_bib26","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1055\/a-0620-8135","article-title":"Fully vs. partially covered selfexpandable metal stent for palliation of malignant esophageal strictures: a randomized trial (the COPAC study)","volume":"50","author":"Didden","year":"2018","journal-title":"Endoscopy"},{"key":"10.1016\/j.ejca.2020.04.032_bib27","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1007\/s00464-017-5441-0","article-title":"Fully covered stents are similar to semi-covered stents with regard to migration in palliative treatment of malignant strictures of the esophagus and gastric cardia: results of a randomized controlled trial","volume":"31","author":"Persson","year":"2017","journal-title":"Surg Endosc"},{"key":"10.1016\/j.ejca.2020.04.032_bib28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1055\/a-0644-2495","article-title":"Self-expandable metal stent placement for malignant esophageal strictures-changes in clinical outcomes over time","volume":"51","author":"Reijm","year":"2019","journal-title":"Endoscopy"},{"key":"10.1016\/j.ejca.2020.04.032_bib29","first-page":"24","article-title":"Effectiveness of several external beam radiotherapy schedules for palliation of esophageal cancer","volume":"17","author":"Walterbos","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.prro.2011.12.002","article-title":"Palliative radiotherapy in patients with esophageal carcinoma: a retrospective review","volume":"2","author":"Murray","year":"2012","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12029-010-9206-4","article-title":"Palliative stenting with or without radiotherapy for inoperable esophageal carcinoma: a randomized trial","volume":"43","author":"Javed","year":"2012","journal-title":"J Gastrointest Canc"},{"key":"10.1016\/j.ejca.2020.04.032_bib32","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.ijrobp.2017.06.2457","article-title":"Toxicity and outcomes in patients with and without esophageal stents in locally advanced esophageal cancer","volume":"99","author":"Francis","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2020.04.032_bib33","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/jjco\/hye053","article-title":"Self-expandable metallic stents for patients with recurrent esophageal carcinoma after failure of primary chemoradiotherapy","volume":"31","author":"Muto","year":"2001","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib34","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1120\/jacmp.v14i4.4218","article-title":"Self-expanding stent effects on radiation dosimetry in esophageal cancer","volume":"14","author":"Francis","year":"2013","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.ejca.2020.04.032_bib35","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S2468-1253(17)30363-1","article-title":"Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicenter randomised controlled trial (TROG 03.01)","volume":"3","author":"Penniment","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejca.2020.04.032_bib36","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0167-8140(00)00225-5","article-title":"A prospective trial of short-course radiotherapy plus chemotherapy for palliation of dysphagia from advanced esophageal cancer","volume":"56","author":"Hayter","year":"2000","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib37","first-page":"1","article-title":"Palliative short-course hypofractionated radiotherapy followed by chemotherapy in esophageal adenocarcinoma: the phase II PALAESTRA trial","volume":"28","author":"Borg","year":"2019","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib38","first-page":"32","article-title":"Effects of neoadjuvant chemoradiotherapy vs chemotherapy alone on the relief of dysphagia in esophageal cancer patients: secondary endpoint analysis in a randomized trial","volume":"1","author":"Sunde","year":"2019","journal-title":"Dis Esophagus"},{"key":"10.1016\/j.ejca.2020.04.032_bib39","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","article-title":"Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial","volume":"3","author":"Al-Batran","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib40","doi-asserted-by":"crossref","first-page":"741","DOI":"10.4251\/wjgo.v11.i9.741","article-title":"Detection and management of oligometastatic disease in oesophageal cancer and identification of prognostic factors: a systematic review","volume":"11","author":"Jamel","year":"2019","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib41","doi-asserted-by":"crossref","first-page":"S226","DOI":"10.1016\/S0167-8140(19)30851-5","article-title":"Esophageal brachytherapy: Institut Gustave Roussy\u2019s experience","volume":"133","author":"Kissel","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib42","article-title":"Low-dose versus high-dose radiation therapy for the palliation of dysphagia from esophageal cancer: a multicenter retrospective cohort study","author":"Vermeulen","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib43","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.radonc.2010.09.001","article-title":"Adding external beam to intra-luminal brachytherapy improves palliation in obstructive squamous cell oesophageal cancer: a prospective multi-centre randomized trial of the International Atomic Energy Agency","volume":"97","author":"Rosenblatt","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib44","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S0140-6736(04)17272-3","article-title":"Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial","volume":"364","author":"Homs","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2020.04.032_bib45","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1442-2050.2005.00467.x","article-title":"Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial","volume":"18","author":"Bergquist","year":"2005","journal-title":"Dis Esophagus"},{"key":"10.1016\/j.ejca.2020.04.032_bib46","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(14)70131-7","article-title":"Conventional stents versus stents loaded with (125)iodine seeds for the treatment of unresectable oesophageal cancer: a multicentre, randomized phase 3 trial","volume":"15","author":"Zhu","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib47","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.radonc.2013.04.008","article-title":"Palliative brachytherapy with or without primary stent placement in patients with oesophageal cancer, a randomised phase III trial","volume":"107","author":"Amdal","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2020.04.032_bib48","doi-asserted-by":"crossref","first-page":"1233e6","DOI":"10.1016\/j.dld.2016.07.003","article-title":"Underuse of brachytherapy for the treatment of dysphagia owing to esophageal cancer. An Italian survey","volume":"48","author":"Fuccio","year":"2016","journal-title":"Dig Liver Dis."},{"key":"10.1016\/j.ejca.2020.04.032_bib49","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3109\/0284186X.2012.731521","article-title":"Patient-reported outcomes evaluating palliative radiotherapy and chemotherapy in patients with oesophageal cancer: a systematic review","volume":"52","author":"Amdal","year":"2013","journal-title":"Acta Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920302355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920302355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:27:56Z","timestamp":1760732876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920302355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":49,"alternative-id":["S0959804920302355"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.04.032","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.04.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}